Sputnik V protection from COVID-19 in people living with HIV under antiretroviral therapy.

Autor:	Gushchin VA; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Tsyganova EV; Moscow City Center for AIDS Prevention and Control, Moscow, Russia., Ogarkova DA; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Adgamov RR; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Shcheblyakov DV; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Glukhoedova NV; Moscow City Center for AIDS Prevention and Control, Moscow, Russia., Zhilenkova AS; Moscow City Center for AIDS Prevention and Control, Moscow, Russia., Kolotii AG; Autonomous Noncommercial Organization, Moscow Center for Innovative Technology in Health Care, Moscow, Russia., Zaitsev RD; Autonomous Noncommercial Organization, Moscow Center for Innovative Technology in Health Care, Moscow, Russia., Logunov DY; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Gintsburg AL; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Mazus AI; Moscow City Center for AIDS Prevention and Control, Moscow, Russia.
Jazyk:	angličtina
Zdroj:	EClinicalMedicine [EClinicalMedicine] 2022 Mar 24; Vol. 46, pp. 101360. Date of Electronic Publication: 2022 Mar 24 (Print Publication: 2022).
DOI:	10.1016/j.eclinm.2022.101360
Abstrakt:	Background: HIV-infection is known to aggravate the course of many infectious diseases, including COVID-19. International guidance recommends vaccination of HIV+ individuals against SARS-CoV-2. There is a paucity of data on epidemiological efficacy assessment of COVID-19 vaccines among HIV+. This paper provides a preliminary assessment of Sputnik V vaccine effectiveness in HIV+ patients on antiretroviral therapy (ART). Methods: We performed a retrospective cohort study to assess the effectiveness of the standard Sputnik V vaccination regimen in 24,423 HIV+ Moscow residents during spring - summer 2021, that included dominance of delta variant, with estimation of hospitalization and severe illness rates in vaccinated and unvaccinated patients. Data were extracted from the Moscow anti-COVID-19 vaccination and COVID-19 incidence Registries. Findings: The data obtained indicate that Sputnik V epidemiological efficiency in the entire cohort of HIV+ on ART was 76·33%; in HIV+ with CD4+ ≥ 350 cells/µl, vaccine efficiency was 79·42%, avoiding hospitalization in 90·12% cases and protecting from the development of moderate or severe disease in 97·06%. For delta variant in this group the efficiency was 65·35%, avoiding the need for hospitalization in 75·77% cases and protecting from the development of moderate or severe disease in 93·05% of patients. There was a trend, although not statistically significant, of declining vaccine efficiency in immune-compromised individuals (CD4+ < 350 cells/µl). Interpretation: The study suggested epidemiological efficiency of immunization with Sputnik V in HIV+ ART-treated patients for the original and delta SARS-CoV-2 variants. Funding: Ministry of Health of Russia and Moscow Healthcare Department. Competing Interests: ALG, DYL, DVS have patent pending for the Sputnik V immunobiological expression vector, pharmaceutical agent, in COVID-19 research. The patent owner is the “National Research Center for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya” of the Ministry of Health of the Russian Federation (Moscow, Russia). All other authors declare no competing interests. (© 2022 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu